OSAKA, Japan & CAMBRIDGE, Mass. (BUSINESS WIRE) Takeda (TSE:4502/NYSE:TAK) today announced that, following discussions with the U.S. Food and Drug Administration (FDA), it will be working with the FDA towards a voluntary withdrawal of EXKIVITY® (mobocertinib) in the U.S. for adult patients with epidermal growth fa.
Takeda TSE4502NYSETAK today announced that following discussions with the U.S. Food and Drug Administration FDA it will be working with the FDA towards a voluntary withdrawal of EXKIVITY mobocertinib in the U.S. for adult patients with epidermal growth factor receptor EGFR Exon20 ion mutationpositive ion locally advanced or metastatic nonsmall cell lung cancer NSCLC whose disease has progressed on or after platinumbased chemotherapy.